Show simple item record

dc.creatorGanesan, Shyamala
dc.creatorAcosta, Hugo
dc.creatorBrigolin, Chris
dc.creatorOrange, Kallista
dc.creatorTrabbic, Kevin
dc.creatorChen, Charles
dc.creatorLien, Chia-En
dc.creatorLin, Yi-Jiun
dc.creatorLin, Meei-Yun
dc.creatorChuang, Ya-Shan
dc.creatorFattom, Ali
dc.creatorBitko, Vira
dc.identifier.citationGanesan S, Acosta H, Brigolin C, Orange K, Trabbic K, Chen C, et al. (2022) Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. PLoS ONE 17(11): e0272594.
dc.description.abstractWith the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their efficacy against SARS-CoV-2 infection of upper respiratory tract and transmission is at best temporary. Development of safe and efficacious vaccines that are able to induce robust mucosal and systemic immune responses are needed to control new variants. In this study, we have used our nanoemulsion adjuvant (NE01) to intranasally (IN) deliver stabilized spike protein (S-2P) to induce immunogenicity in mouse and hamster models. Data presented demonstrate the induction of robust immunity in mice resulting in 100% seroconversion and protection against SARS-CoV-2 in a hamster challenge model. There was a significant induction of mucosal immune responses as demonstrated by IgA- and IgG-producing memory B cells in the lungs of animals that received intranasal immunizations compared to an alum adjuvanted intramuscular vaccine. The efficacy of the S-2P/NE01 vaccine was also demonstrated in an intranasal hamster challenge model with SARS-CoV-2 and conferred significant protection against weight loss, lung pathology, and viral clearance from both upper and lower respiratory tract. Our findings demonstrate that intranasal NE01-adjuvanted vaccine promotes protective immunity against SARS-CoV-2 infection and disease through activation of three arms of immune system: humoral, cellular, and mucosal, suggesting that an intranasal SARS-CoV-2 vaccine may play a role in addressing a unique public health problem and unmet medical need.
dc.format.extent15 pages
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartPLoS ONE, Vol. 17, No. 11
dc.relation.isreferencedbyPublic Library of Science
dc.rightsAttribution CC BY
dc.subjectSARS CoV 2
dc.subjectVaccination and immunization
dc.subjectViral vaccines
dc.subjectMucosal immunity
dc.subjectImmune response
dc.subjectVaccine development
dc.titleIntranasal Nanoemulsion Adjuvanted S-2P Vaccine Demonstrates Protection in Hamsters and Induces Systemic, Cell-Mediated and Mucosal Immunity in Mice
dc.type.genreJournal article
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.temple.creatorChen, Charles

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY